Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DS03090629 |
Synonyms | |
Therapy Description |
DS03090629 inhibits Mek1/2, which potentially decreases tumor cell proliferation and tumor growth (PMID: 36622773). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DS03090629 | DS-03090629|DS 03090629 | MEK1 Inhibitor 26 MEK2 Inhibitor 24 | DS03090629 inhibits Mek1/2, which potentially decreases tumor cell proliferation and tumor growth (PMID: 36622773). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E | melanoma | predicted - sensitive | DS03090629 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, DS03090629 inhibited Erk and Mek phosphorylation and proliferation in a melanoma cell line harboring BRAF V600E in culture and led to tumor stasis in a cell line xenograft model (PMID: 36622773). | 36622773 |
BRAF V600E MAP2K1 F53L | melanoma | sensitive | DS03090629 | Preclinical - Cell culture | Actionable | In a preclinical study, DS03090629 inhibited Erk and Mek phosphorylation and proliferation in a melanoma cell line harboring BRAF V600E and expressing MAP2K1 F53L in culture (PMID: 36622773). | 36622773 |
BRAF V600E NRAS Q61K | melanoma | predicted - resistant | DS03090629 | Preclinical - Cell culture | Actionable | In a preclinical study, DS03090629 inhibited Erk but not Mek phosphorylation and did not inhibit proliferation in a melanoma cell line harboring BRAF V600E and expressing NRAS Q61K in culture (PMID: 36622773). | 36622773 |
BRAF V600E BRAF over exp | melanoma | predicted - sensitive | DS03090629 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, DS03090629 inhibited Erk but not Mek phosphorylation and proliferation in a melanoma cell line overexpressing BRAF V600E in culture and led to tumor stasis in a cell line xenograft model (PMID: 36622773). | 36622773 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|